Erschienen in:
24.10.2016 | Hepatobiliary Tumors
Robotic Versus Open Hepatectomy for Hepatocellular Carcinoma: A Matched Comparison
verfasst von:
Po-Da Chen, MD, Chao-Ying Wu, MD, Rey-Heng Hu, MD, PhD, Wei-Han Chou, MD, Hong-Shiee Lai, MD, PhD, Jin-Tung Liang, MD, PhD, Po-Huang Lee, MD, PhD, Yao-Ming Wu, MD, PhD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 4/2017
Einloggen, um Zugang zu erhalten
Abstract
Background
Robotic hepatectomy has been suggested to be a safe and effective approach for liver disease; however, studies comparing robotic hepatectomy with the conventional open approach regarding oncologic outcomes for hepatocellular carcinoma (HCC) are limited. Accordingly, we performed a matched comparison of surgical and oncological outcomes between robotic and open hepatectomy.
Methods
Between January 2012 and October 2015, a total of 183 patients underwent robotic hepatectomy and 275 patients underwent open hepatectomy by the same surgical team in our center. Eighty-one newly diagnosed HCC cases in each group were compared under propensity score matching (PSM) in a 1:1 ratio.
Results
With robotic hepatectomy, the conversion rate was 1.6 % and the complication rate was 4.4 %. On PSM, the groups had a comparable percentage of major liver resections (41.9 vs. 39.5 %) and liver cirrhosis (45.7 vs. 46.9 %). Compared with the open group, the robotic group required longer operation times (343 vs. 220 min), shorter hospital stays (7.5 vs. 10.1 days), and lower dosages of postoperative patient-controlled analgesia (350 vs. 554 ng/kg). The 3-year disease-free survival of the robotic group was comparable with that of the open group (72.2 % vs. 58.0 %; p = 0.062), as was the 3-year overall survival (92.6 vs. 93.7 %; p = 0.431).
Conclusions
This is the first oncological study comparing robotic liver resection for HCC with open resection. Robotic hepatectomy can be applied for challenging major resections in patients with cirrhotic liver disease with less postoperative pain and shorter hospital stays without compromising oncological outcomes.